CG Oncology, Inc. (CGON) Stock Forecast
CGON analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.60 / 5 from 15 analysts
- Price target
- $91.08 average of analyst targets
- Upside to target
- +52.2% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-0.86
- 52-week range
- $37.37 – $80.68
CGON analyst ratings
15 analystsNumber of analysts at each rating.
CGON price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CGON earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.81 | −$0.96 | −$0.66 | −$0.57 | −42.0% | 12 |
| Current fiscal year (2026) | −$3.23 | −$3.60 | −$2.79 | −$2.08 | −55.3% | 12 |
| Next fiscal year (2027) | −$3.02 | −$3.63 | −$2.15 | −$3.23 | +6.5% | 12 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CGON revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $534,480 | $0 | $1.2M | −67.9% | 12 |
| Current fiscal year (2026) | $4.5M | $2.2M | $18.2M | +10.6% | 13 |
| Next fiscal year (2027) | $83.5M | $0 | $183.0M | +1,768.5% | 13 |
CGON EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CGON revenue: reported and forecast
CGON EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.67 | −$0.67 | −$0.82 | −$0.81 | −$0.81 | +21.3% | 0 up · 10 down |
| Current fiscal year (2026) | −$2.66 | −$2.67 | −$3.20 | −$3.20 | −$3.23 | +21.6% | 0 up · 10 down |
| Next fiscal year (2027) | −$2.78 | −$2.78 | −$2.90 | −$3.02 | −$3.02 | +8.7% | 2 up · 7 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CGON earnings surprises
Reported EPS vs the consensus estimate for the last 11 quarters; CGON beat in 3 of 11.
What analysts expect from CGON
15 analysts cover CG Oncology; their consensus rating is strong buy (4.60 on a 1–5 scale, where 5 is a strong buy). The average price target is $91.08, 52.2% above the latest close of $59.85. Analysts expect earnings of −$3.23 per share for 2026, −55.3% from a year earlier. For 2027 the average estimate is −$3.02 per share on revenue of $83.5 million. CG Oncology beat the EPS estimate in 3 of the last 11 quarters.
Related: CGON income statement, CGON key metrics, CGON chart. See the CGON stock overview for the latest quote and news.
CGON forecast FAQ
What is CG Oncology's price target?
The average analyst price target for CG Oncology is $91.08, 52.2% above the latest close of $59.85.
Is CG Oncology a buy, hold or sell?
Of 15 analysts covering CG Oncology, 10 rate it a strong buy, 4 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is CG Oncology's EPS forecast?
Analysts forecast −$3.23 per share for 2026 (range −$3.60 to −$2.79); for 2027 the estimate is −$3.02.
What is CG Oncology's revenue forecast?
The average revenue estimate for 2026 is $4.5 million, growth of 10.6%; for 2027 it is $83.5 million.
When does CG Oncology report earnings?
CG Oncology is expected to report results for the quarter ending September 30, 2026 on November 13, 2026; the EPS estimate is $-0.86.
Does CG Oncology usually beat earnings estimates?
CG Oncology reported EPS at or above the analyst estimate in 3 of the last 11 quarters.